{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:16:33Z","timestamp":1782890193976,"version":"3.54.5"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5629","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T22:07:55Z","timestamp":1456783675000},"page":"427-435","source":"Crossref","is-referenced-by-count":4,"title":["Antihypertensive Efficacy of the Direct Renin Inhibitor Aliskiren as Add-on Therapy in Patients with Poorly Controlled Hypertension"],"prefix":"10.2169","volume":"55","author":[{"given":"Shigemasa","family":"Tani","sequence":"first","affiliation":[{"name":"Department of Health Planning Center, Nihon University Hospital, Japan"},{"name":"Department of Cardiology, Nihon University Hospital, Japan"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kushiro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Health Planning Center, Nihon University Hospital, Japan"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kawamata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nihon University Hospital, Japan"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Ohkubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nihon University Hospital, Japan"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nihon University Hospital, Japan"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am Hypertens 28: 355-361, 2015.","DOI":"10.1093\/ajh\/hpu151"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Boggia J, Asayama K, Li Y, Hansen TW, Mena L, Schutte R. Cardiovascular risk stratification and blood pressure variability on ambulatory and home blood pressure measurement. Curr Hypertens Rep 16: 470, 2014.","DOI":"10.1007\/s11906-014-0470-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. McBrien K, Rabi DM, Campbell N, et al. Intensive and standard blood pressure argets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 172: 1296-1303, 2012.","DOI":"10.1001\/archinternmed.2012.3147"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Torraca S, Palmese S, Sirico ML, Di Micco L, Salvi P, Di Iorio B. Does brachial blood pressure need to predict cardiovascular outcomes in end stage renal disease? An update. Curr Hypertens Rev 9: 60-65, 2013.","DOI":"10.2174\/1573402111309010009"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 1: 221-228, 2006.","DOI":"10.2215\/CJN.01201005"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Azizi M, Ménard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109: 2492-2499, 2004.","DOI":"10.1161\/01.CIR.0000131449.94713.AD"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24: 243-256, 2006.","DOI":"10.1097\/01.hjh.0000202812.72341.99"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Murray AV, Koenig W, Garcia-Puig J, Patel S, Uddin A, Zhang J. Safety and efficacy of aliskiren\/amlodipine\/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. J Clin Hypertens (Greenwich) 14: 821-827, 2012.","DOI":"10.1111\/j.1751-7176.2012.00706.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 29: 997-1005, 2006.","DOI":"10.1291\/hypres.29.997"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res 32: 169-175, 2003.","DOI":"10.1038\/hr.2008.21"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review. J Hum Hypertens 23: 495-502, 2009.","DOI":"10.1038\/jhh.2008.162"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ogihara T, Kikuchi K, Matsuoka H, et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3-107, 2009.","DOI":"10.1038\/hr.2009.34"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Parving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213, 2012.","DOI":"10.1056\/NEJMoa1208799"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsuo S, Imai E, Horio M, et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31: 1281-1357, 2013.","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 119: 417-425, 2009.","DOI":"10.1161\/CIRCULATIONAHA.107.750745"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Andersen K, Weinberger MH, Constance CM, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst 10: 157-167, 2009.","DOI":"10.1177\/1470320309342407"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Vaidyanathan S, Reynolds C, Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the novel oral diect renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 47: 453-460, 2007.","DOI":"10.1177\/0091270006297921"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 15: 92-100, 2013.","DOI":"10.1111\/jch.12032"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Abe M, Maruyama N, Suzuki H, et al. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. Hypertens Res 35: 874-881, 2012.","DOI":"10.1038\/hr.2012.45"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gilbert CJ, Gomes T, Mamdani MM, et al. No increase in adverse events during aliskiren use among Ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Can J Cardiol 29: 586-591, 2013.","DOI":"10.1016\/j.cjca.2013.02.015"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Maddury SR, Pande A, Haque KM, et al. Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting. Adv Ther 30: 176-189, 2013.","DOI":"10.1007\/s12325-013-0005-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yoshitomi Y, Kawanishi K, Yamaguchi A, et al. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension. Int Heart J 54: 88-92, 2013.","DOI":"10.1536\/ihj.54.88"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/5\/55_55.5629\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T07:15:13Z","timestamp":1498288513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/5\/55_55.5629\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5629","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}